Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5,427 JPY

Average target price

6,177 JPY

Spread / Average Target

+13.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+45.82%	64.1B
ELI LILLY AND COMPANY	+56.86%	823B
NOVO NORDISK A/S	+44.08%	641B
JOHNSON & JOHNSON	-6.57%	352B
MERCK & CO., INC.	+17.32%	324B
ABBVIE INC.	+9.94%	301B
ASTRAZENECA PLC	+15.79%	241B
ROCHE HOLDING AG	+1.43%	223B
NOVARTIS AG	+12.89%	218B
AMGEN INC.	+7.98%	167B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 02/07/2024 BST			5-day change	1st Jan Change
5,646 ^JPY	+4.04%		+1.58%	+45.82%

05:32am	Financials lift Japanese shares on rate-hike speculation	RE
04:28am	Daiichi Sankyo Buys Back 13.5 Billion Yen Worth of Shares in June	MT

Financials lift Japanese shares on rate-hike speculation	04:32am	RE
Daiichi Sankyo Buys Back 13.5 Billion Yen Worth of Shares in June	03:28am	MT
Sanofi eyes German insulin investment of up to $1.6 bln, source says	07-01	RE
Daiichi Sankyo Buys Back Shares	07-01	MT
Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2024.	07-01	CI
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	06-27	DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	06-27	CI
Health Care Down as Moderna Slides -- Health Care Roundup	06-26	DJ
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients	06-19	MT
Daiichi Sankyo to Dispose of 320 Million Yen Worth of Shares as Restricted Shares Remuneration	06-18	MT
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May	06-04	MT
Transcript : Daiichi Sankyo Company, Limited - Special Call	06-04
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	06-03	MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	06-03	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results	06-02	RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels	06-02	RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	06-02	RE
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial	06-02	CI
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population	06-02	CI
RevolKa Signs Master Service Agreement with Daiichi Sankyo	05-28	CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	05-27	DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	05-27	MT
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival	05-27	MT
Astra, Daiichi hail positive survival data for Dato-DXd	05-27	AN